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Menten equation' to 'Microaggregates' - nothing very
exciting there. But between them we have 'Michelin tyre
baby', 'Mickey Finn', 'Mickey Mouse appearance', 'Mickey
Mouse ears', 'Mickey Mouse figures' (see 'Mariners wheel'),
and '"Mickey Mouse" medicine' (a derogatory reference to
non-patient-orientated duties that impact upon physicians'
time). A few pages earlier we learn that 'Love canal' is not a
pseudo-medical term used by tabloid newspapers but, in fact,
a water channel near Niagara Falls, dug in 1892 by William
Love and subsequently used as a dump for toxic waste.
However, for readers who may consider that a little tedious,
it is closely followed by 'Lover's heels' - a comminuted
intra-articular fracture of the os calcis with severe crush
injury to the bones of the foot with major anatomic distor-
tions, described in 'jilted' lovers who jump from major
heights.
I think that my favourite entry of the several hundred that
I've read so far is for the '"Jumping Frenchmen of Maine"
syndrome' - a culture-specific complex that is evoked in the
members of a religious sect paradoxically originating from
Wales and residing in North America, the rites of which
include jumping, rolling on the ground, barking like dogs
and so on until a state of ecstasy is achieved!
How does one go about compiling such a dictionary and
how does one check the accuracy of the entries? I don't
know, but I decided to do an independent check by selecting
40 entries relevant to cancer biology and asking colleagues to
give marks out of ten for accuracy and completeness. The
mean mark was 6.7 which can't be bad. Despite this, how-
ever, there are examples of major inaccuracies. The entry on
'MDR' claims, quite wrongly, that 'MDR gene expression is
amplified in methotrexate resistance'. The entry on 'Tumor
suppressor gene' incorrectly includes NM23, ras and tyrosine
kinase gene on chromosome 3 in the list. 'Doxorubicin' has
two different entries, one out of alphabetical order, and
probably meant to describe 'daunorubicin'! The description
of a 'linear accelerator' states that it emits cobalt-60 irradia-
tion. Clearly, therefore, each entry has not been rigorously
checked by an expert in the field and consequently the reader
should feel obliged to obtain an independent check of the
precise details of the more technical terms. Hopefully such
inaccuracies will be eliminated in future editions as they are
unacceptable in a reference book. Nevertheless, the dic-
tionary does an excellent job of 'pointing the reader in the
right direction'.
This book can be strongly recommended for the shelves of
anyone who considers him or herself to be involved in
'modern medicine'. Not only is it scientifically valuable, it
provides an excellent way of spending the odd spare moment
which can be both instructive and entertaining. I'm glad that
I had the opportunity to review the volume and I'm glad that
it now has a permanent place in the BJC editorial office.
P.R. Twentyman
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'Prospects for Antisense Nucleic Acid Therapy of Cancer and
AIDS' is definitely a book for those who enjoy good science
fiction. Some of the best storytellers of the antisense field
have been brought together in a single volume to produce a
work which is both entertaining and rich in fantasy. How-
ever, the title is to some extent misleading since a significant
proportion of the book is concerned with dissecting gene
function in cell cultures using antisense approaches to ablate
gene expression, and therapeutic prospects are hardly men-
tioned, if at all. Indeed, some of the chapters would be more
appropriately placed within a treatise on oncogenes, in view
of the fact that the rambling speculations are entirely con-
cerned with the action of the particular oncoprotein and
contain but passing reference to the antisense strategies pur-
ported to have produced the observed effects.
There are 17 chapters in all and topics covered include
antisense RNA, oligodeoxynucleotides and oligodeoxynucleo-
tide analogues, as applied against oncogenes and HIV, novel
oligodeoxynucleotide derivatives, and basic principles of tri-
ple helix forming antigene oligodeoxynucleotides. In addi-
tion, some preliminary pharmacokinetic and toxicological
data are presented. As regards antisense RNA, it would
appear that the only therapeutic prospect for this approach is
in the ex vivo generation of HIV-resistant haemopoietic cells
for reinfusion into the patient. However, a very interesting
chapter by Yokoyama on myc antisense RNA draws atten-
tion to a new mechanism, namely the induction of protein(s)
which inhibit transcription, thereby raising the spectre that
multi-gene related phenotypes might result from application
of the antisense RNA technique if similar promoter elements
in other genes were also to be affected by the factors induced.
A majority of the antisense oligonucleotide chapters are
concerned with the normal phosphodiester structure which
has no therapeutic potential whatsoever, as a consequence of
nuclease sensitivity and poor cell uptake characteristics.
However, three chapters describe results with comparatively
nuclease-resistant phosphorothioate oligodeoxynucleotide
analogues and another chapter deals in detail with resistant
methylphosphonates. In general, the classical antisense oligo-
nucleotide experiment is described, where effects of antisense
oligonucleotides on mRNA, protein, cell growth, or colony
formation, in conjunction with negative sense or nonsense
sequence controls, obviously prove that the antisense oligo-
nucleotides must have entered the cells and hybridised
specifically with the target mRNAs. The editor, in his own
chapter, goes so far as to simply ignore the highly significant
inhibition of c-myc p65 expression induced by his control,
scrambled sequence oligodeoxynucleotide, while another
chapter claims sequence-specific effects for short (8 and 11
base) ras antisense methylphosphonate oligodeoxynucleotide
analogues, which, on the basis of statistical probability alone,
would be expected to recognise a variety of different
mRNAs.
Amazingly, the book contains minimal reference to the
cellular pharmacology of the oligonucleotides themselves.
However, where people have looked at what is happening to
oligonucleotides in cells, extensive degradation of normal
phosphodiester structures has been observed, and, in the case
of fluorescently labelled polyanionic oligonucleotides, the
usual picture has been one of brilliantly glowing endosomes
surrounding a nuclear black hole. On the other hand, Leser-
man et al., in their chapter, report that when membrane
barriers are circumvented by direct intracytoplasmic microin-
jection, oligodeoxynucleotides are rapidly localised within the
nucleus by avid binding to nuclear proteins. So it would
appear that any antisense molecule lucky enough to escape
the endosome before reaching the lysosomal execution
chamber would only have a limited time on the loose to find
its RNA home. Furthermore, how can the specificity of
action against the target mRNA be guaranteed, when the
opportunity exists for comparatively strong interaction with
non-targeted nucleic acids through regions of substantial par-
tial complementarity? These are some of the considerations
of relevance to the therapeutic exploitation of antisense
oligonucleotides which the book fails to address. The two
chapters on triple helix forming antigene oligodeoxynucleo-
tides are intriguing in terms of the basic science involved,
although this approach offers little therapeutic prospect as
yet.
Of course, there is nothing wrong with a little fantasy to
stimulate research, but the worry is that failure of premature
and ill-conceived clinical trials might jeopardise future real-
isation of the true therapeutic potential of antisense. In terms
of the latter, 'Prospects for Antisense Nucleic Acid Therapy
of Cancer and AIDS' provides but little enlightenment.
D.M. Tidd